NCT02585973 - Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 26, 2015

Primary Completion Date

June 14, 2019

Study Completion Date

June 23, 2021

Conditions

Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG

AZD1775

AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.

DRUG

Cisplatin

40 mg/m2 IV infused over 1 hour D1 of each week of radiation

RADIATION

Intensity Modulated Radiotherapy Treatments

Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks

Trial Locations (1)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill